Biogen has given investors a pleasant surprise with better-than-expected profits in Q3, but has puzzled analysts with a rapid slowdown for its new rare disease drug Spinraza.
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.